Author: Fiona Craig

Tracsis (LSE:TRCS) has agreed to sell its Events Transport Planning & Management division to private investment firm Connection Capital in a cash transaction with an enterprise value of £7.25 million. The business provides transport planning and traffic management services for major outdoor events and venues across the UK and operated as a largely standalone unit within Tracsis’ Data, Analytics, Consultancy and Events division.

During the financial year ended 31 July 2025, the business generated approximately £20.4 million in revenue and £1.9 million in adjusted EBITDA.

Disposal Supports Shift Towards Higher-Margin Software

The sale marks another step in Tracsis’ strategy of concentrating on scalable software solutions and increasing the proportion of recurring revenue generated across the group. Management believes the disposal will allow the company to focus more closely on technology-led products that offer stronger long-term growth potential and higher margins.

The transaction also simplifies the group’s operating structure while reinforcing its strategic emphasis on software and data-driven transport solutions.

Sale Proceeds to Reduce Debt Following Acquisition

Funds raised from the disposal will be used primarily to reduce net debt following Tracsis’ recently announced acquisition of Mistral Data. Strengthening the balance sheet is expected to improve the group’s financial flexibility while supporting continued investment in its core software platforms and future growth initiatives.

Management confirmed that trading expectations for the 2026 financial year remain unchanged.

Financial Stability Supports Long-Term Outlook

Tracsis continues to benefit from a solid financial position, supported by a healthy balance sheet and improving cash generation. The shares have also maintained a positive long-term technical trend.

However, profitability metrics remain relatively weak, while the company’s high price-to-earnings ratio and modest dividend yield limit valuation support despite its favourable strategic positioning.

About Tracsis

Tracsis is a UK transport technology company providing software, hardware and data-driven services to the rail, traffic management and wider transport sectors. Its products help customers improve operational efficiency, optimise infrastructure performance, enhance safety and deliver better passenger experiences.

The company operates across the UK and North America, offering transport software, analytics, geographic information systems (GIS) and data capture solutions to transport operators, infrastructure managers and public sector organisations.

EnSilica (LSE:ENSI) has been awarded a €1.7 million contract to deliver the second phase of a satellite communications application-specific integrated circuit (ASIC) programme for a leading European satellite manufacturer. The 10-month project will focus on developing the system architecture, advanced signal processing algorithms and a working demonstrator, further strengthening the company’s expertise in designing high-performance communications chips for the space sector.

New Programme Builds Satellite Technology Capabilities

The latest contract expands EnSilica’s involvement in the satellite payload programme and reinforces its position as a supplier of specialist semiconductor technology for complex space applications. By progressing into the next development stage, the company aims to deepen its technical capabilities while strengthening relationships within the European satellite industry.

Management believes the project will support future opportunities in the fast-growing market for advanced communications infrastructure.

EU 5G Satellite Project Opens New Growth Opportunities

Alongside the contract award, EnSilica has joined the European 5G-aNTeNna consortium, which is developing user terminal technology for the European Union’s IRIS² satellite constellation.

As part of the project, the company will provide application-specific standard products (ASSPs) for satellite user terminals, expanding its presence beyond satellite payload technology into the ground segment of Europe’s sovereign satellite communications network. The initiative also positions EnSilica to benefit from the emerging 5G non-terrestrial network (5G-NTN) market.

Financial Challenges Continue Despite Strategic Progress

Although EnSilica continues to secure strategically important contracts, its financial outlook remains constrained by declining revenue, ongoing losses and weaker free cash flow.

Technical indicators have improved considerably in recent months, reflecting stronger share price momentum. However, signs that the stock may be overbought suggest the potential for short-term volatility. Valuation also remains challenging given the company’s loss-making position and the absence of a dividend.

About EnSilica plc

EnSilica plc is a fabless semiconductor company specialising in the design of application-specific integrated circuits for communications, industrial, automotive and space applications. Its expertise spans radio frequency (RF), millimetre-wave, mixed-signal and complex digital chip design.

The company develops reusable intellectual property and silicon platforms to shorten product development cycles and reduce engineering risk for customers. EnSilica operates design centres in the UK, India, Brazil and Hungary, serving clients across international technology markets.

HICL Infrastructure (LSE:HICL) has reported a positive start to its financial year, with its investment portfolio performing in line with expectations and growth-focused assets benefiting from ongoing capital expenditure programmes that are supporting higher EBITDA. During the period, the company strengthened its position in Cross London Trains by acquiring an additional 6.65% interest for approximately £52 million, increasing its total ownership to 13.13%.

Management expects the larger stake to deliver a modest uplift in net asset value (NAV) per share while giving HICL greater influence over the governance of one of its key transport investments.

Strategy Targets Higher Long-Term Returns

At its capital markets seminar in July, HICL outlined the next stage of its strategic development, aiming to generate medium-term total shareholder returns of more than 10%. The company plans to achieve this through disciplined capital allocation and selective investment in higher-return infrastructure opportunities while maintaining its focus on essential core assets.

The board also reaffirmed its progressive dividend policy, maintaining dividend targets of 8.50 pence per share for the financial year ending March 2027 and 8.65 pence for 2028.

Strong Liquidity Supports Shareholder Returns

HICL continued its share buyback programme during the period, repurchasing shares at a meaningful discount to net asset value. Management also highlighted the company’s strong liquidity position, resilient cash flows from its public-private partnership (PPP) investments and favourable long-term trends supporting global infrastructure investment.

These factors are expected to provide a solid platform for future capital allocation and continued shareholder distributions.

Financial Strength Underpins Outlook

The company’s investment case continues to benefit from a debt-free balance sheet, positive free cash flow and an attractive valuation supported by a relatively low price-to-earnings ratio and a high dividend yield.

Technical indicators remain constructive, with the shares continuing to trade in an upward trend, although momentum measures suggest the stock may be approaching overbought territory. Revenue variability remains one of the principal risks to the company’s longer-term outlook.

About HICL Infrastructure PLC

HICL Infrastructure PLC is a London-listed infrastructure investment company managed by InfraRed Capital Partners. The company invests in a diversified portfolio of essential infrastructure assets, including transport, utilities, communications infrastructure and public-private partnership (PPP) projects.

Its strategy focuses on generating stable, inflation-linked cash flows and delivering progressive dividends through disciplined investment management and a well-diversified portfolio of long-term infrastructure assets.

Intercede Group (LSE:IGP) has secured approximately $2.6 million in new contract awards and renewals, while also identifying around $1.65 million of additional renewal opportunities extending through to early 2030. The latest agreements were generated through the company’s partner network and include a mix of software licences, subscription contracts and professional services projects for customers across government, defence and other critical sectors.

New Business Expands Public Sector Presence

The newly announced contracts cover deployments of Intercede’s MyID CMS platform through both perpetual and subscription licensing models. Customers include U.S. federal agencies, a multinational military alliance, European public sector organisations and clients based in the Middle East.

The company also secured a number of professional services engagements supporting existing customers in the defence, aerospace and U.S. government sectors, further strengthening long-term client relationships.

Strong Pipeline Supports FY2027 Outlook

Management said the latest contract wins demonstrate healthy pipeline conversion and provide positive momentum at the beginning of FY2027. Intercede continues to focus on growing recurring revenue by maintaining a balanced mix of software licences, subscriptions and consulting services.

The company believes this diversified commercial model positions it well for sustainable medium-term growth despite ongoing macroeconomic uncertainty and geopolitical risks.

Solid Profitability Offsets Softer Revenue Trends

Intercede’s outlook continues to benefit from strong profitability and a conservatively financed balance sheet with low leverage. However, recent declines in revenue and cash generation compared with 2024 remain areas for investors to monitor.

Technical indicators also remain relatively weak, with the shares trading below their major moving averages. While the valuation appears reasonable, with a price-to-earnings ratio of approximately 16.4, this has yet to fully offset concerns surrounding slowing growth and weaker market momentum.

About Intercede Group

Intercede Group is a cybersecurity software company specialising in digital identity and credential management solutions. Its flagship MyID platform helps organisations protect users and systems through secure identity registration, authentication and credential lifecycle management.

The company’s technology supports password security, public key infrastructure (PKI), FIDO authentication, one-time passwords and identity verification services for customers across government, defence, financial services, healthcare and other highly regulated industries worldwide.

RWS Holdings (LSE:RWS) has reached an agreement to acquire Acogroup, the parent company of European language services provider Acolad, in a transaction with an enterprise value of £22.4 million. The acquisition will bring a business generating approximately £182 million in annual revenue into the group, significantly expanding RWS’s presence across Western Europe and strengthening its relationships with multinational clients operating in regulated industries.

The acquired business will become part of RWS’s Transform division, where management plans to combine Acolad’s capabilities with its existing AI-powered language and content solutions.

Acquisition Aims to Accelerate AI-Driven Growth

The transaction values Acogroup at around two times its expected adjusted EBITDA for the financial year ending September 2027. Total consideration of £40.2 million will be financed through RWS’s existing credit facilities.

Management expects the acquisition to create opportunities to expand the use of its AI-based Generate and Protect platforms, broaden its interpreting services and increase investment in new technology products. The deal remains subject to regulatory approval in France and consultation with employee representative bodies, with completion expected during the first half of FY2027.

Strategic Benefits Offset Recent Trading Challenges

RWS believes the acquisition will strengthen its competitive position by expanding its customer base, increasing cross-selling opportunities and enhancing its portfolio of AI-enabled language services.

However, the company’s broader outlook continues to be affected by weaker financial performance, including declining revenue, pressure on margins and recent losses. Technical indicators also remain subdued, with the share price trading below key moving averages.

Despite these challenges, RWS continues to benefit from a relatively solid balance sheet and an attractive dividend yield, which provide some support for the investment case.

About RWS Holdings

RWS Holdings is a global provider of AI-powered language, content and intellectual property solutions, helping organisations communicate effectively across international markets. The company combines linguistic expertise with artificial intelligence to deliver translation, localisation, content management and language technology services for large enterprises.

Its portfolio includes AI-driven platforms such as Cultural Intelligence Layer and Language Weaver Pro, with a particular focus on highly regulated sectors where accuracy, compliance and multilingual content management are critical.

CelLBxHealth plc (LSE:CLBX) has announced that its Parsortix platform featured in an independent, peer-reviewed study demonstrating the technology’s ability to identify key antibody-drug conjugate (ADC) biomarkers on circulating tumour cells (CTCs) from patients with triple-negative breast cancer and epithelial ovarian cancer. The findings add to the growing body of evidence supporting the platform’s application in precision oncology and treatment monitoring.

Study Demonstrates Detection of Key Cancer Biomarkers

The research, carried out by investigators in Dublin and published in The Journal of Liquid Biopsy, showed that the Parsortix system successfully detected clinically relevant biomarkers including TROP-2, FRα and PD-L1 on circulating tumour cells. Importantly, the platform was able to identify these targets even on tumour cells with low EpCAM expression, highlighting its ability to capture a broader and more diverse population of CTCs than conventional approaches.

The results reinforce the technology’s potential value in monitoring the biological changes that occur during cancer treatment.

Opportunity in the Expanding ADC Market

CelLBxHealth believes the study supports the use of Parsortix as a minimally invasive tool for real-time biomarker assessment within the fast-growing antibody-drug conjugate market, where changes in target expression can influence treatment selection and effectiveness.

Management said the findings are consistent with the company’s strategy of focusing on high-value applications for circulating tumour cell analysis across research, pharmaceutical development and translational oncology. The additional clinical evidence could help strengthen relationships with drug developers and healthcare professionals seeking more advanced methods of monitoring patient response to therapy.

Financial Challenges Continue to Temper Outlook

Despite the positive scientific validation, CelLBxHealth continues to face significant financial headwinds. Weak financial performance and negative technical indicators remain the primary factors affecting the company’s overall outlook.

While recent corporate developments and progress highlighted during earnings updates provide some encouragement, concerns surrounding profitability and valuation continue to weigh on investor sentiment.

About CelLBxHealth plc

CelLBxHealth plc is a biotechnology company specialising in circulating tumour cell intelligence for cancer research, drug development and clinical oncology. Its patented Parsortix platform isolates circulating tumour cells from blood samples for downstream imaging, genomic and proteomic analysis, supporting the development of personalised cancer treatments.

The company generates revenue through sales of Parsortix instruments and consumables, laboratory services for clinical studies, assay development and the expansion of laboratory-developed testing programmes through both partnerships and internal initiatives.

GCP Infra (LSE:GCP) reported a net asset value (NAV) of 98.60 pence per share as of 30 June 2026, supported by a diversified portfolio of 47 infrastructure investments with a combined value of £810.4 million. The portfolio delivers a weighted average annualised yield of 8.0% and has an average remaining life of 11 years, with many assets benefiting from partial inflation-linked income.

The company also confirmed that its online investor portal has been updated with the latest quarterly valuation data, giving shareholders greater transparency into the composition and performance of the portfolio.

Capital Recycling Enhances Liquidity

During the period, GCP Infra continued to strengthen its financial position through a series of capital management initiatives. Borrowings under its revolving credit facility were reduced from £24.0 million to zero, while the company repurchased more than 19 million of its own shares, leaving it with only a modest level of net debt.

The investment company also completed several portfolio optimisation transactions, including introducing third-party financing into its solar assets, which generated approximately £40 million in additional cash. It further completed the sale of an anaerobic digestion project and two onshore wind assets at prices above their previous carrying values, improving liquidity while crystallising value for shareholders.

Stable Financial Position Supports Outlook

GCP Infra’s outlook continues to be supported by a conservative balance sheet, improving cash generation and favourable technical market indicators. These strengths are complemented by shareholder-friendly capital allocation policies, including share buybacks and a stable dividend.

However, revenue trends have been mixed in recent periods, while the company’s valuation remains relatively demanding despite its attractive dividend yield. Even so, management believes the portfolio’s defensive characteristics and disciplined capital management provide a solid foundation for long-term returns.

About GCP Infrastructure Investments Ltd

GCP Infrastructure Investments Ltd is a FTSE 250-listed closed-ended investment company focused on infrastructure debt and related assets across the UK. Its portfolio primarily consists of projects backed by long-term public sector or availability-based revenue streams, with many investments offering partial protection against inflation.

The company has also been awarded the London Stock Exchange’s Green Economy Mark in recognition of the positive environmental contribution of its investment portfolio.

Genedrive plc (LSE:GDR) has welcomed the publication of a new UK clinical guideline endorsing MT-RNR1 genotype testing before the use of aminoglycoside antibiotics in situations where results can be delivered quickly enough to influence treatment decisions. The Manchester-based diagnostics company believes the guidance strengthens the case for broader adoption of its rapid point-of-care genetic testing technology across the NHS and supports its strategy of expanding precision medicine in acute healthcare settings.

New Guidance Endorses Rapid Genetic Testing

The guideline, published in the British Journal of Clinical Pharmacology, recommends testing patients for MT-RNR1 genetic variants before administering aminoglycoside antibiotics whenever clinically relevant turnaround times can be achieved. The publication also recognises the value of point-of-care testing and specifically references the Genedrive MT-RNR1 ID Kit, which is currently the only point-of-care MT-RNR1 test routinely used in neonatal intensive care units across the UK.

Management described the new guidance as an important step towards increasing the adoption of pharmacogenetic testing within emergency and neonatal care.

NHS Expansion Opportunity Strengthens Growth Prospects

According to Genedrive, the clinical guideline complements the existing NICE Early Value Assessment, which concluded that the MT-RNR1 ID Kit has the potential to improve patient outcomes while reducing healthcare costs compared with standard treatment pathways.

The company expects additional evidence from the PALOH-UK programme to contribute to NICE’s planned review, which could further support wider NHS deployment of the test. If adopted more broadly, the technology could strengthen Genedrive’s commercial position in the growing pharmacogenomics market while creating new opportunities for revenue growth in the UK and overseas.

Financial Performance Continues to Present Challenges

Despite the positive clinical developments, Genedrive continues to face financial headwinds. The company remains loss-making, continues to consume cash and has seen its equity base decline, although debt levels remain relatively low.

Technical indicators offer a more balanced outlook, with the share price trading above its major moving averages and momentum signals remaining broadly neutral. However, valuation remains constrained by the absence of earnings and a lack of dividend support.

About Genedrive plc

Genedrive plc is a UK commercial-stage molecular diagnostics company specialising in rapid point-of-care pharmacogenetic testing. Its products are designed to help clinicians make safer prescribing decisions in emergency and acute care by identifying genetic variations that influence a patient’s response to specific medicines.

The company’s portfolio includes the Genedrive CYP2C19 ID Kit, which identifies stroke patients who may not respond effectively to Clopidogrel, and the MT-RNR1 ID Kit, which helps prevent aminoglycoside-related hearing loss in newborns. Through these technologies, Genedrive aims to expand the use of precision medicine across healthcare systems in the UK and international markets.

GoldStone Resources (LSE:GRL) has started a 2,000-metre reverse circulation drilling campaign at its Homase Mine in Ghana as part of plans to strengthen future gold production. The programme will focus on the proposed Pit 5 and Pit 6 oxide deposits, with the objective of improving the definition of near-surface mineralisation, refining resource models and supporting mine planning while increasing confidence in recoverable reserves across the Homase Trend.

Drilling Targets Mine Life and Resource Growth

The latest exploration programme forms part of GoldStone’s wider strategy to increase its available mining inventory and provide greater operational flexibility along the Homase structural corridor, which extends for more than four kilometres.

During the six months ended 30 June 2026, the company produced approximately 46.43 kilograms of doré gold and sold 1,214.4 ounces. Although operations were affected by Ghana’s seasonal rains, GoldStone continued investing in infrastructure upgrades designed to improve production efficiency and reduce weather-related disruptions.

Processing Plant Upgrades Aim to Improve Recovery Rates

To enhance operational performance, the company is installing higher-capacity pumps, upgrading its adsorption circuit and expanding heap leach pad capacity. GoldStone is also adding new mining equipment to improve plant reliability and increase gold recovery rates as production ramps up.

Management believes these investments will strengthen the resilience of operations while supporting more consistent output in the future.

Financial Challenges Remain Despite Operational Progress

While operational development continues, GoldStone’s financial outlook remains constrained by widening losses and ongoing cash outflows, despite improving revenue. The absence of earnings and dividend payments also limits valuation support.

Technical indicators present a more balanced picture, with the share price trading above its major moving averages and the relative strength index remaining moderately positive. However, weaker momentum reflected by a negative MACD suggests investor sentiment remains mixed.

About GoldStone Resources

GoldStone Resources is an AIM-listed gold exploration, development and production company focused on projects in Ghana and West Africa. Its flagship Akrokeri-Homase project hosts a JORC-compliant gold resource of 602,000 ounces across a four-kilometre section of the Homase Trend, covering the Homase North, Homase Pit and Homase South deposits, together with two historic mining areas.

In addition to operating the Homase heap leach mine in Ghana, the company is pursuing further regional growth through a 50% interest in a gold project in Sierra Leone located adjacent to the Boamuhun Gold Mine.

Microlise Group (LSE:SAAS) delivered a resilient first-half performance for fiscal 2026, with growth in high-quality recurring revenue helping to offset weaker demand from original equipment manufacturers (OEMs) and lower hardware sales. Although total revenue declined during the period, the company significantly improved profitability and strengthened its cash position, leaving management confident of achieving its full-year earnings expectations.

Recurring Revenue Continues to Grow

Direct customer annual recurring revenue increased 12% year on year to £47.1 million, with recurring income now representing 76% of total group revenue. Overall revenue fell 10% to £39.5 million, reflecting softer OEM activity and continued pressure on hardware volumes.

Despite the decline in sales, adjusted EBITDA margin improved to 13.2% following restructuring measures and tighter cost controls. Net cash also increased to £13.8 million, demonstrating the company’s strong cash generation and disciplined financial management despite ongoing supply chain challenges.

Strategic Investment Targets Future Growth

Microlise continues to invest in initiatives designed to support long-term expansion, including the rollout of its Microlise One platform, the development of new artificial intelligence capabilities and the expansion of its sales organisation.

Management believes these investments, combined with robust demand from direct customers, a healthy sales pipeline and projects delayed by hardware shortages, will help accelerate revenue growth and improve profitability from FY2027 onwards.

Strong Balance Sheet Supports Long-Term Outlook

The company’s outlook continues to benefit from a healthy balance sheet and positive free cash flow generation. However, recent operating performance remains affected by a sharp reduction in reported revenue and continued losses, while ongoing component shortages and subdued OEM demand continue to create near-term challenges.

Technical indicators remain weak, with the share price trading well below its major moving averages and momentum remaining negative. Although the dividend yield offers some support to investors, the company’s loss-making position continues to weigh on its overall valuation.

About Microlise Group plc

Microlise Group plc is a UK-based provider of fleet management and transport technology solutions for logistics operators. Its software and hardware products help customers improve operational efficiency, enhance driver safety, reduce emissions and optimise fleet performance.

Founded in 1982, the company serves more than 2,500 customers worldwide and operates from its headquarters in Nottingham, with additional offices in France, Australia and India. Microlise is also recognised with the London Stock Exchange’s Green Economy Mark for its contribution to sustainable transport technologies.